Results 301 to 310 of about 44,321 (338)

Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: a case report of elranatamab and a literature review. [PDF]

Ann Hematol
Ogiya D, Suzuki R, Goto S, Nakagawa Y, Nasukawa M, Iwata S, Kawai H, Toyosaki M, Machida S, Onizuka M, Ogawa Y, Kawada H.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Engineering bispecific antibodies

Current Opinion in Biotechnology, 1993
Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
P, Holliger, G, Winter
openaire   +2 more sources

Bispecific Antibodies in Lymphoma

International Reviews of Immunology, 1993
Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J, Demanet, Christian, Moser, Muriel, Leo, Oberdan, Thielemans, Kris   +4 more
openaire   +2 more sources

Production of Bispecific Antibodies

Current Protocols in Immunology, 1995
AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
David M, Segal, Bert J E G, Bast
openaire   +2 more sources

Immunotherapeutic perspective for bispecific antibodies

Immunology Today, 2000
Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
A B, van Spriel, H H, van Ojik, J G, van De Winkel   +2 more
openaire   +2 more sources

Diabodies: small bispecific antibody fragments

Cancer Immunology, Immunotherapy, 1997
Although bispecific antibodies (bAb) are widely recognised to offer great promise in the therapy of malignancies and other diseases, significant difficulties in their production and purification have limited their progress to clinical application. Techniques employed to overcome this bottleneck in the production of clinical-grade bAb (starting from ...
P, Holliger, G, Winter
openaire   +2 more sources